These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19672628)

  • 41. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Wang J; Fan Y; Xu B
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
    Oostendorp LJ; Stalmeier PF; Donders AR; van der Graaf WT; Ottevanger PB
    Lancet Oncol; 2011 Oct; 12(11):1053-61. PubMed ID: 21621462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
    Oliva C; Bergnolo P; Inguì M; Bianco L; Pochettino P; Cutin SC; Boglione A; Dal Canton O; Garetto F; Comandone A
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):411-7. PubMed ID: 19727815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Andres R; Mayordomo JI; Lara R; Lastra R; Ortega E; Polo E; Lambea J; Isla D; Saenz-Cusi A; Escudero P; Tres A
    Clin Breast Cancer; 2005 Jun; 6(2):158-62. PubMed ID: 16001994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
    Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
    Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
    J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The evolving role of capecitabine in breast cancer.
    O'Shaughnessy JA
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S20-5. PubMed ID: 12756075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes.
    Mao W; Guan X; Tucker S; Li F; He Z; Wang J; Guo J; Wu S
    Chemotherapy; 2011; 57(1):71-6. PubMed ID: 21293121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
    Zelek L; Barthier S; Riofrio M; Fizazi K; Rixe O; Delord JP; Le Cesne A; Spielmann M
    Cancer; 2001 Nov; 92(9):2267-72. PubMed ID: 11745280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
    Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer.
    Razis E; Kosmidis P; Aravantinos G; Bakoyiannis C; Janinis J; Timotheadou H; Christodoulou C; Fountzilas G
    Cancer Invest; 2004; 22(1):10-5. PubMed ID: 15069759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Schmid P; Kühnhardt D; Kiewe P; Lehenbauer-Dehm S; Schippinger W; Greil R; Lange W; Preiss J; Niederle N; Brossart P; Freier W; Kümmel S; Van de Velde H; Regierer A; Possinger K
    Ann Oncol; 2008 May; 19(5):871-6. PubMed ID: 18209010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
    Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
    J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
    Martí JL; Bueso P; Mayordomo JI; Isla MD; Saenz A; Escudero P; Murillo L; Filipovich E; Andres R; Tres A
    Ann Oncol; 2001 Aug; 12(8):1061-5. PubMed ID: 11583186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
    Stemmler HJ; diGioia D; Freier W; Tessen HW; Gitsch G; Jonat W; Brugger W; Kettner E; Abenhardt W; Tesch H; Hurtz HJ; Rösel S; Brudler O; Heinemann V
    Br J Cancer; 2011 Mar; 104(7):1071-8. PubMed ID: 21407218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.